NEW IPA 3.0 DEPLOYED TO SPRI RESEARCHERS
Redwood City, CA– October 12, 2005 – Ingenuity announced today that Schering-Plough Research Institute, the global pharmaceutical research arm of Schering-Plough Corporation has licensed both IPA and the IPA Integration Module (IPA-IM).
IPA 3.0 (IPA), released last month, enables biologists and bioinformaticians to model, analyze, and understand the complex biological systems at the core of all life science research. IPA leverages the world largest and highest quality knowledge base of biological networks and powerful algorithms, along with an exceptionally easy-to-use software interface, to provide researchers with the insights and confidence needed to make better and faster decisions at every step of their research.
With access to the new release of IPA 3.0, scientists will now be able to integrate their own biological relationships with Ingenuity pathways to create custom networks for particular targets, biomarkers, disease areas, and processes and enable powerful computation and functional analysis. Researchers will also benefit from IPA 3.0’s vastly expanded search capabilities and a doubling of the gene and disease content.
IPA is available as a web-delivered, hosted, or deployed solution.
Fully functional complimentary trials are available to qualified scientists at www.ingenuity.com/trial/start.html.
Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotechnology companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan. www.ingenuity.com.